Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Bleeding Time Study With AZD6482, Clopidogrel and ASA

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-03-02
Last Posted Date
2009-08-19
Lead Sponsor
AstraZeneca
Target Recruit Count
28
Registration Number
NCT00853450
Locations
🇸🇪

Research Site, Lund, Sweden

Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-02-19
Last Posted Date
2015-05-06
Lead Sponsor
Peking University First Hospital
Target Recruit Count
200
Registration Number
NCT00847860
Locations
🇨🇳

Peking University First Hospital, Beijing, Beijing, China

🇨🇳

Shanghai Hua Shan Hospital, Shanghai, Shanghai, China

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

First Posted Date
2009-02-02
Last Posted Date
2016-04-27
Lead Sponsor
Celgene Corporation
Target Recruit Count
259
Registration Number
NCT00833833
Locations
🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 16 locations

Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy

First Posted Date
2009-01-22
Last Posted Date
2013-04-12
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
2500
Registration Number
NCT00827411
Locations
🇫🇷

Institut de Cardiologie- Hopital la Pitié Salpétrière, Paris, France

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

First Posted Date
2009-01-15
Last Posted Date
2019-03-27
Lead Sponsor
Boston Scientific Corporation
Target Recruit Count
1530
Registration Number
NCT00823212
Locations
🇺🇸

Maine Medical Center, Portland, Maine, United States

🇺🇸

Washington Adventist Hospital, Takoma Park, Maryland, United States

🇺🇸

Ohio Health Research and Innovation Institute, Columbus, Ohio, United States

and more 128 locations

Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation

First Posted Date
2009-01-14
Last Posted Date
2014-10-17
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
1798
Registration Number
NCT00822536
Locations
🇫🇷

Hopital la Pitié Salpêtrière Institut de Cardiologie, Paris, France

Aspirin Responsiveness in Women at Risk for Cardiac Events

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-01-07
Last Posted Date
2012-12-04
Lead Sponsor
Creighton University
Target Recruit Count
36
Registration Number
NCT00818337
Locations
🇺🇸

The Cardiac Center at Creighton University, Omaha, Nebraska, United States

COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke

First Posted Date
2008-12-24
Last Posted Date
2014-02-28
Lead Sponsor
Sanofi
Target Recruit Count
358
Registration Number
NCT00814268
Locations
🇰🇷

Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of

Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic Patients

Phase 4
Completed
Conditions
First Posted Date
2008-12-19
Last Posted Date
2022-05-27
Lead Sponsor
Karolinska Institutet
Target Recruit Count
25
Registration Number
NCT00812032
Locations
🇸🇪

Department of Medicine, Clinical pharmacology Unit, Karolinska University Hospital, Solna., Stockholm, Sweden

Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)

First Posted Date
2008-11-27
Last Posted Date
2022-02-24
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
682
Registration Number
NCT00799396
Locations
🇺🇸

Amish Research Clinic, Lancaster, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath